AC Immune (NASDAQ:ACIU) reported disappointing topline results from a Phase 2 trial evaluating semorinemab for the treatment of early Alzheimer’s disease (AD).
Semorinemab, an anti-tau antibody, did not meet its primary efficacy endpoint of reducing decline on clinical dementia rating-sum of boxes, compared with placebo. The drug candidate also failed to meet two secondary endpoints: the AD assessment scale-cognitive subscale 13 and the AD cooperative study group – activities of daily living inventory.
“Today’s news is surprising and disappointing, given what we as a field know about tau and its strong spatiotemporal correlation with both symptoms and pathology in AD,” Andrea Pfeifer, AC Immune’s CEO, said in a statement.
“We believe the full data analysis of this first-of-its-kind study will yield information about this promising target that will advance our understanding and inform future efforts to successfully develop effective therapeutics for neurodegenerative diseases,” she added.
